Termination of Alzex Biomedical Group Inc. Agreement

REBEL CAPITAL 2.0 CORP.

TERMINATION OF ALZEX BIOMEDICAL GROUP INC. AGREEMENT

TSX Venture: RBZ.P FOR IMMEDIATE RELEASE

CALGARY, ALBERTA – September 25, 2020 – Rebel Capital 2.0 Corp. (" Rebel" or the

"Corporation") announces that it has terminated its business combination agreement with

Alzex Biomedical Group Inc. effective immediately.

The Company is exploring new business opportunities with a view to undertaking a transaction

which would constitute Rebel's "Qual ifying Transaction" (as such term is defined in TSX

Venture Exchange ("TSXV") Policy 2.4 – Capital Pool Companies).

About Rebel Capital 2.0 Corp.

Rebel Capital is a capital pool company ("CPC") within the meaning of the policies of the TSXV

that has not commenced commercial operations and has no assets other than cash. The board

of directors of the Corporation consist of Charles MaLette, Doug Bachman and Lance Morginn.

The officers of the Corporation are Charles MaLette (CEO), and Lance Morginn (CFO).

The TSX Venture Exchange Inc. has neither approved nor disapproved the contents of this Press Release.

For further information please contact:

Rebel Capital 2.0 Corp.: Alzex Bio Medical Inc.:

Charles MaLette Fern Turner – Director

Email: [email protected] Email: [email protected]

Telephone: (604) 428-5171